Merck & Co., Inc. $MRK Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its stake by 7.3% in Q4, selling 176,199 shares and now holding 2,251,284 shares of Merck ( about 0.09% of the company, valued at ~$239 million).
• A late‑stage clinical setback — the Phase 3 LITESPARK‑012 combination failed to meet primary endpoints in first‑line advanced renal cell carcinoma — has been a near‑term negative catalyst, contributing to the stock trading down roughly 3.8%.
• Offsetting news includes recent regulatory wins (FDA approval of IDVYNSO, priority review for KEYTRUDA+Padcev, EU approval for ENFLONSIA) and multiple analyst upgrades, leaving a consensus "Moderate Buy" with an average target price of $128.47.

Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,251,284 shares of the company's stock after selling 176,199 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.09% of Merck & Co., Inc. worth $239,026,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. DLD Asset Management LP lifted its stake in shares of Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the period. Legal & General Group Plc lifted its stake in shares of Merck & Co., Inc. by 5.9% during the third quarter. Legal & General Group Plc now owns 20,659,157 shares of the company's stock worth $1,733,923,000 after buying an additional 1,156,112 shares during the period. Invesco Ltd. lifted its stake in shares of Merck & Co., Inc. by 16.6% during the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock worth $1,665,585,000 after buying an additional 2,821,766 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock worth $1,336,877,000 after buying an additional 2,735,459 shares during the period. Finally, Nordea Investment Management AB lifted its stake in shares of Merck & Co., Inc. by 2.0% during the third quarter. Nordea Investment Management AB now owns 10,945,187 shares of the company's stock worth $876,600,000 after buying an additional 209,759 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA approves IDVYNSO (doravirine/islatravir), a once‑daily, two‑drug, non‑INSTI HIV‑1 regimen for virologically suppressed adults — expands Merck’s HIV portfolio and offers a new, potentially commercial product line. FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
• Positive Sentiment: FDA grants priority review for KEYTRUDA in combination with Padcev for cisplatin‑eligible muscle‑invasive bladder cancer — a label expansion that could boost Keytruda sales if approved. FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev®
• Positive Sentiment: European approval for ENFLONSIA (RSV antibody) to protect infants — another commercial approval adding to Merck’s vaccine/antibody franchise. Merck Wins EU Approval for ENFLONSIA to Protect Infants from RSV
• Neutral Sentiment: Merck launched a bio‑based solvent portfolio for HPLC (renewable feedstocks) — a sustainability/operational product launch with modest near‑term revenue impact but supports ESG positioning. Merck Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
• Neutral Sentiment: Industry reports reaffirm the growing immuno‑oncology market and Keytruda’s leading position — a supportive macro narrative but high R&D and pricing risks remain. Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035
• Negative Sentiment: Merck and Eisai said their Phase 3 LITESPARK‑012 combination in first‑line advanced renal cell carcinoma failed to meet primary endpoints — the late‑stage setback is the main near‑term negative catalyst and is driving the share decline today. Merck‑Eisai's combination cancer therapy fails to meet main goals of late‑stage study

Wall Street Analyst Weigh In

Several research firms have recently commented on MRK. Wells Fargo & Company lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. UBS Group boosted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Monday, April 13th. Wolfe Research upgraded shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 target price for the company in a research report on Thursday, January 8th. Finally, Citigroup boosted their target price on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the company a "neutral" rating in a research report on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $128.47.

Insiders Place Their Bets

In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of the company's stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer owned 90,192 shares in the company, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Chirfi Guindo sold 20,000 shares of the company's stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the transaction, the chief marketing officer owned 80,615 shares of the company's stock, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Insiders own 0.09% of the company's stock.

Merck & Co., Inc. Trading Down 3.8%

NYSE MRK opened at $112.63 on Wednesday. The company has a market capitalization of $278.18 billion, a PE ratio of 15.47, a P/E/G ratio of 2.35 and a beta of 0.26. The company has a fifty day moving average of $119.02 and a 200 day moving average of $106.48. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm's quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts forecast that Merck & Co., Inc. will post 4.93 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were given a $0.85 dividend. The ex-dividend date was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.0%. Merck & Co., Inc.'s dividend payout ratio is 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.